Catherine Wheeler

Trophos SA engages in manufacturing and development of pharmaceutical products. It offers medicines to patients with conditions such as amyotrophic lateral sclerosis, spinal muscular atrophy and cardiac ischemia reperfusion injury. The company was founded by Antoine Beret and Michel Delaage in 1991 and is headquartered in Marseille, France.

Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies.

The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research.

France Biotech Association is an independent association founded in 1997 that brings together healthtech entrepreneurs and their expert partners. The non-profit company is based in Paris, France. The association actively contributes to meeting the many challenges of the healthtech industry, such as companies' financing, innovation-related taxes, regulatory and market access related issues. It offers concrete competition and solutions through its commissions and working groups to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients. The French company was founded by Philippe Pouletty, Pascal Brandys, Denis J. Lucquin.

American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA.

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.

Bayer AS trades pharmaceutical products. It also provides animal health, crop science, and consumer health. The company was founded in 1964 and is headquartered in Lysaker, Norway.

BiognoSYS AG operates as a biotechnology company. Its products include iRT Kit, HRM Kit, Sample Prep Kit, PlasmaDive, Spectronaut and SpectroDive. The company was founded by Philipp M. Antoni, Johan Malmstroem and Oliver Rinner on September 3, 2008 and is headquartered in Schlieren, Switzerland.

Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland.

Athyrium Capital Management LP (Athyrium) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Jeffrey A. Ferrell in 2008 as Athyrium Capital Management LLC and converted from a Delaware limited liability company to a Delaware limited partnership in 2015. Athyrium provides advisory services on a discretionary basis to its clients, which may include specific tailored vehicles and pooled investment vehicles intended for sophisticated investors and institutional investors.

Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.

The General Medical Council provides business support services. The non-profit company is based in London, UK. The CEO of the British company is Charlie Massey.

Loxbridge Research LLP operates as an investment and project management company. It specializes in startup, early stage, and later stage investments in growth stage companies. The firm supports scientists and focuses on sectors like science, medicine and healthcare technology particularly biotech, med-tech, noval therapeutic, diagnostics, cancer, infectious diseases, neurodegeneration, imaging hardware and software, and enabling devices. The company was founded by Charles Roberts in 2008 and is headquartered in London, the United Kingdom.

Part of BioLineRx Ltd., Agalimmune Ltd. is a British company that develops anti-cancer immunotherapy technology. The company is based in London, UK. The company was founded by Charles Campbell Roberts and Graham Griffiths. The CEO is Mike Westby. Agalimmune was acquired by BioLineRx Ltd. on March 23, 2017 for $6.05 million.

Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom.

Resolys Bio, Inc. operates as a pharmaceutical company. The firm develops OSLO and MCC for the treatment of certain forms of traumatic brain injury and chronic painful tissue disorders. The company is headquartered in Delanson, NY.

Part of Intas Pharmaceuticals Ltd., Essential Pharmaceuticals LLC is a company that manufactures and markets pharmaceutical products. The company is based in Durham, NC. The company was founded in 2006. Emma Jane Johnson has been the CEO of the company since 2023. Essential Pharmaceuticals was acquired by Accord Healthcare, Inc. on July 26, 2017.

Essential Pharmaceuticals Ltd. manufactures pharmaceutical products. The company was founded on November 24, 2010 and is headquartered in Egham, the United Kingdom.

Cytoseek Ltd. provides cell membrane augmentation technology for enhancement of cell therapies for cancer, heart disease, osteoarthritis, and diabetic wound healing. It enables new functionalities to cell therapies including tissue specific targeting and enhanced cell survivability. The company was founded by Adam Willis Perriman on November 22, 2017 and is headquartered in Bristol, the United Kingdom.

Engitix Ltd. is a preclinical stage biopharma British company that is developing breakthrough therapies for fibrosis and solid tumors using its patient-centric human extracellular matrix drug discovery platform. The company has drug discovery partnerships with Dompe Farmaceutici and Takeda for advanced fibrotic liver diseases and fibrostenotic inflammatory bowel disease. Engitix was established in 2016 to commercialize research from the Institute for Liver and Digestive Health at University College London. The company is headquartered in WestWorks, London, UK. Giuseppe Mazza and Massimo Pinzani founded the company, and Giuseppe Mazza has been the CEO since 2016.

Ichnos Sciences, Inc. operates as a biotechnology company. It provides curative therapies that extend human life. The company was founded in 2019 and is headquartered in Paramus, NJ.

Georgiamune, Inc. is a clinical stage biotechnology company that focuses on reprogramming immune signaling pathways to redirect the immune system to fight diseases. The company is based in Silver Spring, MD. The company has designed unique approaches to re-establish immune balance, and its scientific discoveries have led to pioneering immunotherapies targeting high unmet needs. Georgiamune's lead program, Gim-122, is a first-in-class, dual-functioning monoclonal antibody designed to overcome immune therapy resistance in cancer patients. In addition to its lead program, the company is advancing a pipeline of first-in-class therapies for cancer and autoimmune diseases. The company was founded by Samir N. Khleif, a world-renowned medical oncologist and researcher in the field of immunology and cancer, based on discoveries in his lab on novel mechanisms to modulate immune response. Samir N. Khleif has been the CEO since incorporation.

Imophoron Ltd. is an American company that specializes in cutting-edge vaccine development. The company's scientific advisory board consists of world-leading experts in vaccine technology and infectious diseases. The company is constantly exploring new and innovative ways to combat infection using the latest techniques from science and technology. More information about the company can be found on their website at www.imophoron.com. The company was founded by Fred Garzoni and Richard Edward Bungay has been the CEO of the company since 2022.

DoMore Diagnostics AS is a Norwegian company located in Oslo that provides cancer diagnostics with artificial intelligence. It was founded in 2020 by Sepp de Raedt and Torbjørn Furuseth. Torbjørn Furuseth has been the CEO since the inception date.